Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Kidney problems news

Show

From To
Tenofovir, boosted atazanavir and boosted lopinavir are associated with cumulative risk of developing chronic kidney disease

Three antiretroviral drugs are associated with a slowly increasing rate of chronic kidney disease over time, the Conference on Retroviruses and Opportunistic Infections (CROI 2015) in

Published
27 February 2015
By
Gus Cairns
Patients with HIV can safely receive kidneys from deceased HIV-positive donors, with good five-year survival rates

HIV-positive patients can safely receive kidneys from deceased HIV-infected donors, investigators from South Africa report in the February 12th edition of the New England Journal of Medicine. 

Published
16 February 2015
By
Michael Carter
Tenofovir-based HIV PrEP does not harm kidneys

Men and women without HIV infection who use tenofovir-based pre-exposure prophylaxis (PrEP) develop significant but not clinically relevant declines in kidney function, according to the largest study to date to look at the issue.

Published
26 December 2014
From
Medscape (requires free registration)
HIV-infected adults diagnosed with age-related diseases at similar ages as uninfected adults

HIV-infected adults are at a higher risk for developing heart attacks, kidney failure and cancer. But, contrary to what many had believed, the researchers say these illnesses are occurring at similar ages as adults who are not infected with HIV.

Published
10 December 2014
From
Science Daily
IDWeek 2014: Longer Use, Age, Low Body Weight Raise Risk of Tenofovir Kidney Problems

Abnormal kidney biomarkers are common but rarely progress to serious kidney dysfunction in HIV positive people taking tenofovir, and longer duration of use, older age, and having diabetes or high blood pressure raise the risk, researchers reported at IDWeek 2014 last week in Philadelphia. A related study found that people with low body weight experienced progressive kidney function decline while taking tenofovir.

Published
20 October 2014
From
HIVandhepatitis.com
Gilead Sciences: A Preview of Important HIV Drug Study Results

Gilead is running nine phase III studies involving tenofovir alafenamide (TAF), which reflects the importance of the drug to Gilead's future HIV business. It is collecting an enormous amount of clinical data in which to make the case that TAF should be a preferred backbone drug for new and existing HIV patients, as well as patients who cannot use Viread because of pre-existing kidney conditions.

Published
23 September 2014
From
The Street
Guidelines Advise Against Tenofovir for HIV Patients With Kidney Disease

HIV-positive patients who have reduced kidney function should take antiretroviral therapy, but should avoid regimens that contain tenofovir (Viread), according to updated treatment guidelines from the HIV Medicine Association (HIVMA).

Published
22 September 2014
From
The Body Pro
Study Dampens HOPE of HIV Organ Donations

The HIV Organ Policy Equity (HOPE) Act, which legalizes research into organ tranplants from HIV-positive donors to HIV-positive recipients, is less than a year old, but a new study already suggests the organs may be of poor quality.

Published
17 September 2014
From
Medscape (requires registration)
Tenofovir HIV PrEP causes no long-term harm to kidneys

HIV pre-exposure prophylaxis (PrEP) with tenofovir is associated with mild disturbances in kidney function that resolve when treatment is stopped, investigators report in the online edition of Clinical

Published
21 May 2014
By
Michael Carter
Risk score can help predict which people living with HIV have highest risk of kidney disease during tenofovir treatment

Investigators in the United States have developed a risk score to predict which people living with HIV have the highest risk of developing chronic kidney disease.

Published
31 March 2014
By
Michael Carter
← First12345...8Next →

Filter by country